225 related articles for article (PubMed ID: 32899586)
1. Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment.
Piccolomo A; Schifone CP; Strafella V; Specchia G; Musto P; Albano F
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899586
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
3. IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML.
Lopez-Millan B; Diaz de la Guardia R; Roca-Ho H; Anguita E; Islam ABMMK; Romero-Moya D; Prieto C; Gutierrez-Agüera F; Bejarano-Garcia JA; Perez-Simon JA; Costales P; Rovira M; Marín P; Menendez S; Iglesias M; Fuster JL; Urbano-Ispizua A; Anjos-Afonso F; Bueno C; Menendez P
Oncoimmunology; 2018; 7(9):e1477460. PubMed ID: 30228947
[TBL] [Abstract][Full Text] [Related]
4. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Pan B; Lentzsch S
Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
7. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
8. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Sinit RB; Hwang DG; Vishnu P; Peterson JF; Aboulafia DM
BMC Cancer; 2019 Nov; 19(1):1147. PubMed ID: 31775673
[TBL] [Abstract][Full Text] [Related]
9. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.
Guo H; Yang J; Wang H; Liu X; Liu Y; Zhou K
Front Immunol; 2022; 13():1017990. PubMed ID: 36311747
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Zeidner JF; Foster MC
Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
[TBL] [Abstract][Full Text] [Related]
11. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Vallet S; Witzens-Harig M; Jaeger D; Podar K
Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes.
Castelli R; Cassin R; Cannavò A; Cugno M
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):1-7. PubMed ID: 23153925
[TBL] [Abstract][Full Text] [Related]
13. [Lenalidomide in hematological malignancies---review].
Jin X; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
[TBL] [Abstract][Full Text] [Related]
15. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
17. Novel immunomodulatory drugs and neo-substrates.
Gao S; Wang S; Song Y
Biomark Res; 2020; 8():2. PubMed ID: 31938543
[TBL] [Abstract][Full Text] [Related]
18. [Research and Applications Progress of Lenalidomide in Relapsed / Refractory Blood System Diseases -Review].
Fan WJ; Fan ZQ; Wu T; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):595-599. PubMed ID: 29665938
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.
Chanan-Khan AA; Swaika A; Paulus A; Kumar SK; Mikhael JR; Rajkumar SV; Dispenzieri A; Lacy MQ
Blood Cancer J; 2013 Sep; 3(9):e143. PubMed ID: 24013664
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
